Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2000-03-01 / Br. J. Haematol. 2000 Mar;108(4):805-16Clinical applications of dendritic cell vaccines
/in Dendritic Cells, International Publications /von 2000-02-01 / Curr. Opin. Mol. Ther. 2000 Feb;2(1):20-8Newcastle disease virus (NDV): brief history of its oncolytic strains
/in International Publications, Newcastle Disease Virus /von 2000-02-01 / J. Clin. Virol. 2000 Feb;16(1):1-15Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2000-02-01 / Med. Oncol. 2000 Feb;17(1):2-15Selenium and immunocompetence in patients with head and neck cancer
/in International Publications, Micronutrients /von 2000-02-01 / Biol Trace Elem Res 2000 Feb;73(2):97-111Temperature-dependent changes in physiologic parameters of spontaneous canine soft tissue sarcomas after combined radiotherapy and hyperthermia treatment
/in Hyperthermia, International Publications, Soft Tissue Sarcoma /von 2000-01-01 / Int. J. Radiat. Oncol. Biol. Phys. 2000 Jan;46(1):179-85Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma
/in Dendritic Cells, International Publications, Multiple Myeloma /von 1999-12-01 / Br. J. Haematol. 1999 Dec;107(3):648-55Tumour cell kinetics as predictors of response in canine lymphoma treated with chemotherapy alone or combined with whole body hyperthermia
/in Hyperthermia, International Publications, Malignant Lymphoma /von 1999-11-01 / Int J Hyperthermia 1999 Nov-Dec;15(6):475-86Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA
/in Colorectal Cancer, Dendritic Cells, International Publications /von 1999-07-02 / Int. J. Cancer 1999 Jul;82(1):121-4
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de